Dabrafenib/Trametinib combination in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes

Home / Abstract / Dabrafenib/Trametinib combination in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes